Yifang Biopharma's TYK2 inhibitor, D-2570, demonstrated significant efficacy in a Phase II trial for moderate to severe plaque psoriasis, with high PASI 75 response rates across multiple dose groups.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.